Replies to post #221131 on Biotech Values

[north40000]

Somewhat different topic, know of your interest, and may directly affect AMGN's Repatha:

http://www.neurologytimes.com/headache-and-migraine/new-insights-dietary-intake-and-headache?rememberme=1&elq_mid=3391&elq_cid=404795


https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143856486

https://www.medpagetoday.com/cardiology/prevention/75271

[DewDiligence]

ESRX’s CGRP coverage—AMGN/NVS,LLY yes—TEVA no:

https://in.reuters.com/article/us-express-scripts-migraine/exclusive-express-scripts-covers-amgen-lilly-migraine-therapies-excludes-teva-drug-idINKCN1MR1IA

Express Scripts…will cover new migraine drugs from Eli Lilly and Amgen Inc, but is excluding a rival medication made by Teva Pharmaceutical Industries Ltd after price negotiations with all three manufacturers.

… All three drugs have a list price of $575 a month, or $6,900 a year. Geoffrey Porges, biotech analyst at Wall Street investment bank Leerink Partners, told Reuters he expects the drugmakers will need to offer rebates of at least 30 percent for the new migraine class to be covered by insurance.

…In May, Amgen and marketing partner Novartis AG won U.S. regulatory approval for Aimovig, an injected drug designed to interfere with a process that helps kick off migraine headaches. Teva’s Ajovy and Lilly’s Emgality were approved last month. The three drugs work in a similar manner…

…Express Scripts already lists Amgen’s Aimovig as a preferred treatment on its largest formulary, but requires that patients first try two older preventive therapies and a triptan, a family of generic drugs used to treat acute migraine. Lilly’s Emgality will be covered under the same terms.

[DewDiligence]

TEVA's 4Q18 Ajovy (CGRP) sales=$3M:

https://finance.yahoo.com/news/teva-reports-fourth-quarter-full-120000531.html

Ajovy launched in the US on 9/14/18, so it had almost a full quarter on the market.

TEVA's Ajovy guidance for 2019 is "~$150M".

[DewDiligence]

LLY/AMGN/NVS/TEVA—US CGRP market—>3-horse race—LLY’s Emgality leads by a nose as free sampling remains high:

https://uk.reuters.com/article/lilly-migraine-share/lillys-new-migraine-drug-pulls-ahead-of-amgen-in-fierce-battle-for-new-prescriptions-idUKL2N22M1D9

Lilly’s therapy Emgality claimed the largest share of first-time patients at 37.7 percent, for the first time outstripping Amgen’s Aimovig, whose share dropped to 37.2 percent as of April 26. Teva came in at a 25.1 percent share…

While Amgen’s therapy was the first to be approved for the U.S. market last May, Lilly has fought to gain more favorable insurance coverage by offering deep discounts. Those efforts appear to have paid off. Lilly is the only drugmaker in the class currently covered by all three of the leading companies that manage Americans’ prescription drug benefits: Cigna Inc’s Express Scripts, UnitedHealth Group’s OptumRx and CVS Health.

…nearly 50 percent of Emgality prescriptions in the quarter [1Q19] were provided at no cost to patients, similar to the proportion of giveaways from Amgen and Teva.